Physician profile
Terri Trumbly
NPI 1730774688
$3,470.41
in general payments reported to CMS, 2019-2025
28 companies · $491 in 2025
The $491 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $196 · 2022: $684 · 2023: $1,342 · 2024: $758 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,569 · Education: $22.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,568.91 |
| Education | $22.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $833.32 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $525.49 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $428.61 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $221.16 | 2021-2023 | |
| Novo Nordisk INC | $180.21 | 2021-2025 | Wegovy |
| Otsuka America Pharmaceutical, INC. | $147.55 | 2023 | Rexulti |
| Astellas Pharma US INC | $125.00 | 2024 | Veozah |
| Janssen Pharmaceuticals, INC | $125.00 | 2023 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $123.22 | 2022-2025 | Seglentis, Livalo, Zoryve |
| Novartis Pharmaceuticals Corporation | $93.08 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $90.23 | 2024-2025 | Voquezna |
| Axsome Therapeutics, INC. | $84.18 | 2024-2025 | Auvelity |
| Lilly USA, LLC | $75.27 | 2022-2023 | Mounjaro, Emgality, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $45.87 | 2023-2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.56 | 2023 | Jardiance |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $39.15 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $37.67 | 2022 | |
| Lundbeck LLC | $36.38 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.29 | 2023 | Xifaxan |
| Philips North America LLC | $32.74 | 2022-2023 | |
| Idorsia Pharmaceuticals US INC | $28.06 | 2023 | Quviviq |
| Acella Pharmaceuticals, LLC | $22.00 | 2023 | NP Thyroid 60 |
| Upsher-Smith Laboratories LLC | $21.14 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.74 | 2022 | |
| Sanofi-Aventis U.S. LLC | $18.63 | 2022 | |
| Pfizer INC. | $15.95 | 2024 | |
| Esperion Therapeutics, INC. | $13.62 | 2025 | Nexletol |
| Inogen, INC. | $6.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terri Trumbly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.